Navigation Links
Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
Date:8/4/2011

CRANBURY, N.J., Aug. 4, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity. AZD2820 is a clinical candidate selected by AstraZeneca from its collaborative research program with Palatin Technologies.

Obesity is a global problem, with the World Health Organization estimating that over 1.5 billion adults are overweight and over 500 million are obese. Worldwide obesity has more than doubled since 1980.  A number of different metabolic and hormonal pathways are being evaluated by companies around the world in efforts to develop better treatments for obesity. Scientific research has established that melanocortin receptors have a role in eating behavior and energy homeostasis, and that some melanocortin receptor agonists decrease food intake and induce weight loss in animal studies.

The single center study is expected to enroll 90 subjects in a randomized, single-blind, placebo-controlled, Phase 1 trial in healthy male volunteers. For more information on this clinical trial with AZD2820, please visit www.clinicaltrials.gov .

"We are very pleased that AstraZeneca has initiated a Phase 1 clinical trial with a collaboration compound, demonstrating AstraZeneca's ongoing commitment and diligence in exploring melanocortin compounds for the treatment of obesity," said Dr. Carl Spana, President and Chief Executive Officer of Palatin.

Pursuant to the terms of the research collaboration and license agreement with AstraZeneca, Palatin is eligible for milestone payments upon achieving development and regulatory milestones and further payments on achievement of sales targets, in addition to roy
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
2. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
3. Palatin Technologies, Inc. Announces Results of Annual Stockholders Meeting
4. Palatin Technologies, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference
5. Palatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
6. Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants
7. Palatin Technologies, Inc. December 31, 2010 Quarter Results; Teleconference and Webcast to be Held on February 24, 2011
8. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2011 Results
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
10. Palatin Technologies, Inc. to Report Fiscal Year 2011 First Quarter Results; Teleconference and Webcast to be Held on November 16, 2010
11. Palatin Announces Strategic Realignment of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... DIEGO , July 28, 2015  Kerastem Technologies ... approval from the U.S. FDA Center For Biologics Evaluation ... Therapies to conduct a clinical trial investigating the safety ... of female and early male pattern baldness (androgenic alopecia). ... STYLE trial, follows initial clinical work in ...
(Date:7/28/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) ... to German life sciences entrepreneurs with a proven ... biotechnology (collectively, the "Optionee"), an option to license ... technology (the "Technology"), including AEZS-120, the most advanced ... to enter a Phase 1 clinical trial. This ...
(Date:7/27/2015)... July 27, 2015  Amgen (NASDAQ: AMGN ) ... financial results on Thursday, July 30, 2015, after the ... be followed by a conference call with the investment ... from Amgen will be Robert A. Bradway , ... Amgen,s senior management team. Live audio of ...
(Date:7/27/2015)... ... ... Production of high tenacity filament yarn of viscose rayon (excluding sewing thread) ... it surpassed the EUR 106 million mark (in value terms) in 2013, while it ... producer, while Italy is a key consumer. , The high tenacity filament yarn ...
Breaking Biology Technology:Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2
... Anca Copaescu, then a second-year MBA in the University of ... Burrill Technology Business Plan Competition, she knew she wanted to ... though the money definitely got her attention. It was the ... of her deepest dreams. "Even as a child growing up ...
... , ,Its a strategy, process and technology ... across the entire spectrum of local, state, national, and ... life sciences and information technology. We can help our ... tourism, manufacturing, and agriculture to operate in real- time. ...
... most common question Im asked is, Why wont angels invest in ... 90+% of the entrepreneurs asking this question. The irony is that ... though it isnt the answer they are expecting. The less ... is serious and problematic. , , Angels vs. angel networks ...
Cached Biology Technology:Romanian Student Leverages Burrill Competition to Accomplish Her Dream 2Romanian Student Leverages Burrill Competition to Accomplish Her Dream 3Real-Time Economy: Part 2 2What Angel Networks Want 2What Angel Networks Want 3What Angel Networks Want 4What Angel Networks Want 5
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ... Generation Biometrics Market by Application, Technology, Function & Geography ... offering. The next generation biometrics market is ... CAGR of 17.9% between 2015 and 2020 ... market. Safran SA ( France ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... discovered the presence of functional ion channels in human ... electrical wires and permit ESCs, versatile cells that possess ... the body, to conduct and pass along electric currents. ... channels in implanted cells, derived from stem cells, they ...
... pathogenic fungi as model systems for understanding fungal diseases, ... offers insight into how carbon dioxide (CO2) governs the ... different environments and invade the human body, and they ... utilize evolutionarily conserved enzymes to control the growth and ...
... medieval Europe ?to fade from the scene? By the ... The reason seems to be, say researchers at the ... a far more deadly disease, overtook leprosy, killing millions ... examination of DNA from human remains from the ancient ...
Cached Biology News:Stem cells' electric abilities might help their safe clinical use 2CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 2CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 3Once-dreaded leprosy 'replaced' by tuberculosis, say researchers 2
Anti-CoralHue Dronpa Green Monoclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Sheep polyclonal to Methaqualone ( Abpromise for all tested applications). Antigen: Methaqualone(5') conjugated to BSA...
... polyclonal to BRF2 Immunogen Synthetic peptide: ... of Human BRF2. Reactivity / Specificity ... species. Background Information BRF2 is one ... III transcription factor complex required for transcription of ...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: